Orbimed Advisors LLC, Director, 10% Owner at Prelude Therapeutics Inc (PRLD), bought 2,815,315 shares at $4.44 ($12.5M) on 2026-04-21, disclosed to the SEC on 2026-04-23.
Open-market purchase of $12.5M PRLD by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.44 | 1,126,126 | $5.0M | 40.0% |
| 2 | $4.44 | 1,689,189 | $7.5M | 60.0% |
| Total | $4.44 avg | 2,815,315 | $12.5M | 100% |
| Filing → |
| BRVE | BUY | 2026-08-11 | $34.9M | — | Filing → |
| SCTX | BUY | 2026-07-29 | $15.0M | — | Filing → |
| SION | SELL | 2026-07-09 | $3.9M | — | Filing → |